Marshall Wace North America’s Bioventus BVS Stock Holding History

Marshall Wace North America’s Portfolio BVS Stock Details BVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-87,046	Closed	-$1.33M	–	1475
2021 Q1	$1.33M	Buy	+87,046	New	+$1.24M	0.01%	948

Other funds holding BVS

EWM

Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Nuance Investments Kansas City, Missouri $717M AUM 3.8% 1-Year Est. Return

PVI

Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Tamarack Advisers Carlsbad, California $2.12M AUM 58.09% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Marshall Wace North America's BVS Position: Q2 2021 in Review

Marshall Wace North America sold out of Bioventus (BVS) in Q2 2021, closing a stake of 87,046 shares — an estimated $1.33M sold.

Marshall Wace North America first reported a position in BVS in Q1 2021 and held it in 1 quarter. The position peaked at $1.33M in Q1 2021. 53 funds tracked by Wall St. Rank hold BVS as of Q2 2021.

Marshall Wace North America reported no remaining Bioventus position as of Q2 2021 after selling out during the quarter.
Marshall Wace North America sold 87,046 Bioventus shares in Q2 2021, an estimated $1.33M.
Marshall Wace North America first reported a position in Bioventus in Q1 2021 and held it in 1 quarter.
Marshall Wace North America's Bioventus position peaked at $1.33M in Q1 2021.
53 funds tracked by Wall St. Rank held Bioventus as of Q2 2021.

Based on Marshall Wace North America's 13F filing for Q2 2021, filed 13 Aug 2021.